GSK Set for $500 Million Payment From mRNA Lawsuit Settlement

CureVac NV has settled a long-running patent dispute over mRNA vaccines with Pfizer Inc. and BioNTech SE in the US, which will see CureVac’s former collaborator GSK Plc receive as much as $500 million and 1% of royalties from future vaccine sales.

The settlement comes as BioNTech looks to close the purchase of its former rival CureVac for about $1.25 billion. GSK will receive $370 million upfront, with another $130 million on the closing of the acquisition.

Shares in GSK rose as much as 1.7% in London.

In the wake of the race to develop Covid-19 vaccines, drugmakers launched multiple ...